These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11048560)

  • 1. [Calculation of costs of stroke, cost effectiveness of stroke units and secondary prevention in patients after a stroke, as recommended by revised CBO practice guideline 'Stroke'].
    Niessen LW; Dippel DW; Limburg M
    Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1959-64. PubMed ID: 11048560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Shah H; Gondek K
    Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
    Chambers M; Hutton J; Gladman J
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
    Matchar DB; Samsa GP; Liu S
    Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
    Hankey GJ
    Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
    Rothlisberger JM; Ovbiagele B
    J Comp Eff Res; 2015 Aug; 4(4):377-84. PubMed ID: 26274799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counting the true cost of antiplatelet therapy for stroke prevention.
    Morton JA; Newton J; Gray CS
    Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Wu B; Kun L; Liu X; He B
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke].
    Claes C; Mittendorf T; Grond M; von der Schulenburg JM
    Med Klin (Munich); 2008 Nov; 103(11):778-87. PubMed ID: 19165429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.
    Burton TM; Lacey M; Liu F; Yu Y; Monsalvo ML; Lang K; Sander S
    J Med Econ; 2012; 15(6):1217-25. PubMed ID: 22857539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
    Haldemann R; Lüscher TF; Szucs TD
    Praxis (Bern 1994); 2001 Mar; 90(13):539-45. PubMed ID: 11550619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
    Brüggenjürgen B; Lindgren P; Ehlken B; Rupprecht HJ; Willich SN
    Eur J Health Econ; 2007 Mar; 8(1):51-7. PubMed ID: 17186199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
    Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
    Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.